

Antibody	Specificity	pSYK activation	Proliferation/survival of macrophages/microglia	AD mouse model (age)	Amyloid burden	Microglia clustering around plaques	Cognition	Citation
4D9	Mouse	Yes	Enhanced	APP-NL-G-F (6mo)	Reduced soluble A β	Not reported	Not reported	Schlepckow et al (2020) (Ref 11)
AL002c	Human	Not reported	Enhanced	5xFAD (5-5.5mo); hTREM2-Bac ¹	Filamentous plaques reduced; inert plaques increased	No change	Improved	Wang et al (2020) (Ref 32)
AL002a	Mouse	Not reported	Not reported	5xFAD (3.5-5mo)	Reduced total A β	Enhanced	Improved	Price et al (2020) (Ref 33)
Ab-T1	Human/mouse	Yes	Enhanced	5xFAD (4-5mo)	Reduced number of diffuse cortical plaques	Enhanced	Improved	Fassler et al (2021) (Ref 34)
T2AB	Human	Yes	Enhanced	5xFAD (5mo; 8mo); hTREM2-Bac ¹	No change in soluble/insoluble A β ²	Not reported	Not reported	Ellwanger et al (2021) (Ref 35)
Ab18	Mouse	Yes	Enhanced	5xFAD (5mo)	Reduced plaque number	Enhanced	Improved	Zhao et al (2022) (Ref 36)
Ab2	Human	Yes	Enhanced	5xFAD (5mo); human microglia grafted into lateral ventricles	Not reported	Enhanced	Not reported	Zhao et al (2022) (Ref 37)
AL002a	Mouse	Yes	Not reported	5xFAD (6mo); injection of AD-tau aggregates from human AD brain tissue	No change	Enhanced	Not reported	Jain et al (2023) (Ref 38)
DNL919	Human	Yes	Enhanced	5xFAD (4.5mo); hTREM2-Bac ¹	Not reported	Not reported	Not reported	Van Lengerich et al (2023) (Ref 39)

1 BAC: bacterial artificial chromosome; 2 Note that only results from an acute treatment were reported.